SARS‑CoV‑2 and Seizure: An Insight Into the Pathophysiology
Description
No abstract
PubMed COVID-19 Clinical Care
2531 - 2540 of 4555 results found
Safety and Immunogenicity against Ancestral, Delta and Omicron Virus Variants Following a Booster Dose of an Inactivated Whole-Virus COVID-19 Vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMP...
Description
CONCLUSION: A booster dose of VLA2001 was safe and well tolerated after primary immunization with VLA2001 and ChAdOx1-S. The tolerability of a booster dose of VLA2001 was similar to the favourable profile observed after the first and second priming
Senses and repercussions of student assistance on the eating practices of students from a Brazilian public university during the COVID-19 pandemic
Description
Student assistance (SA), regulated through the National Student Assistance Program (PNAES), seeks to meet the basic social needs of university students and is inserted in the field of public policies for higher education in federal institutions in
Severe aplastic anemia after BTN162b2 mRNA COVID-19 vaccination in a patient undergoing hemodialysis
Description
Although vaccination against coronavirus infection 2019 (COVID-19) has been found to be effective, reports of adverse reactions continue to appear. We report the development of severe aplastic anemia post BTN162b2 mRNA COVID-19 vaccination in patient
Safety and Immunogenicity against Ancestral, Delta and Omicron Virus Variants Following a Booster Dose of an Inactivated Whole-Virus COVID-19 Vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMP...
Description
CONCLUSION: A booster dose of VLA2001 was safe and well tolerated after primary immunization with VLA2001 and ChAdOx1-S. The tolerability of a booster dose of VLA2001 was similar to the favourable profile observed after the first and second priming
Safety and Immunogenicity against Ancestral, Delta and Omicron Virus Variants Following a Booster Dose of an Inactivated Whole-Virus COVID-19 Vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMP...
Description
CONCLUSION: A booster dose of VLA2001 was safe and well tolerated after primary immunization with VLA2001 and ChAdOx1-S. The tolerability of a booster dose of VLA2001 was similar to the favourable profile observed after the first and second priming
Status quo of urological residency training in Germany-a strengths, weaknesses, opportunities, and threats (SWOT) analysis
Description
CONCLUSIONS: With the help of a SWOT analysis, factors for the further development of urological residency training can be identified. In order to provide high-quality residency training in the future, strengths and opportunities should be
Systematic Review of the Prevalence of Long COVID
Description
CONCLUSIONS: The way in which Long COVID is defined and measured affects prevalence estimation. Given the widespread nature of SARS-CoV-2 infection globally, the burden of chronic illness is likely to be substantial even using the most conservative
Social support and psychosocial well-being among older adults in Europe during the COVID-19 pandemic: a cross-sectional study
Description
CONCLUSION: Findings of the present study highlight a protective role of social support on psychological well-being among both men and women. Developing strategies to promote social support, especially among older adults, may mitigate the rising
Soluble SARS-CoV-2 RBD and human ACE2 peptidase domain produced in Drosophila S2 cells show functions evoking virus-cell interface
Description
The interaction between the receptor binding domain (RBD) of the spike glycoprotein of SARS-CoV-2 and the peptidase domain of the human angiotensin converting enzyme 2 (ACE2), allows the first specific contact at the virus-cell interface making it